Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Role of a novel HLA-DQA1*01:02;DRB1*15:01 mixed-isotype heterodimer in the pathogenesis of 'humanized' multiple sclerosis-like disease.
Multiple sclerosis in US minority populations: Clinical practice insights.
Disruption of Myelin Leads to Ectopic Expression of KV1.1 Channels with Abnormal Conductivity of Optic Nerve Axons in a Cuprizone-Induced Model of Demyelination.
Review: In relapsing-remitting multiple sclerosis, disease-modifying agents reduce annual relapse rates.
Patulous eustachian tube after percutaneous balloon microcompression for trigeminal neuralgia: case report.
IL-6 and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function.
A role for human brain pericytes in neuroinflammation.
n-3 PUFAs Reduce T-Helper 17 Differentiation by Decreasing Responsiveness to Interleukin-6 in Isolated Splenic Mouse CD4+ T Cells.
Statins in neurological disorders: An overview and update.
Epstein-Barr virus in multiple sclerosis.
Functional magnetic resonance imaging movers and shakers: Does subject-movement cause sampling bias?
[Mitoxantrone role in treatment of primary progressive multiple sclerosis].
Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis.
RORγt Expression and Lymphoid Neogenesis in the Brain of Patients with Secondary Progressive Multiple Sclerosis.
Another promising oral agent for multiple sclerosis.
Effects of fatigue on balance and mobility in subjects with multiple sclerosis: a brief report.
An early British case of neuromyelitis optica (1850).
Progression in multiple sclerosis is associated with low endogenous NCAM.
Brain disorders where resources are scarce: The unfinished agenda.
Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS.
Use of the 2010 McDonald Criteria Can Facilitate Early Diagnosis of Pediatric Multiple Sclerosis in a Predominantly Black Cohort.
Response to comment on "dimethyl fumarate (tecfidera): a new oral agent for multiple sclerosis".
Safety and efficacy of reduced fingolimod dosage treatment.
Orthognathic Surgery in a Patient with Multiple Sclerosis.
Sensory dynamic orthoses in mild to moderate upper limb tremor in multiple sclerosis: A mixed methods feasibility study.
Pages
« first
‹ previous
…
392
393
394
395
396
397
398
399
400
…
next ›
last »